PRODUCT DETAILS VIEW ALL PRODUCTS

Vildapride M Tablets (Vildagliptin + Metformin)

  • Each film coated tablet contains Vildagliptin 50 mg + Metformin hydrochloride500/1000mg.
  • For the treatment of type-II diabetes mellitus when single drug therapy along with diet, exercise do not result in adequate glycaemic control.
  • Vildagliptin is a dipeptidyl peptidase-4 inhibitor. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
  • twice daily with meals.
  • Hypersensitivity to the active substance or to any other excipients of the formulation.
  • Not recommended in hepatic impairment, moderate or severe renal impairment. Not recommend in paediatric patients. Risk of decreased vitamin B12 serum levels. Risk of hypoglycemia. Should not be used in patients with type 1 diabetes or for the treatment of diabetic lactic acidosis.
  • There are no adequate and well controlled studies of in pregnant women, nursing women and paediatric population.
  • Vildagliptin has a low potential for drug interactions. No clinically relavant interactions with oral antidiabetic drugs (glibenclamide, pioglitazone, metformin), amlodipine, digoxin, ramipril, simvastatin, valsartan or warfarin were observed after co-adminisatration with vildagliptin. Interaction with Metformin: furosemide, nifedepine, cationic drugs, drugs tending to produce hyperglycemia, alcohol.
  • Most common adverse reactions are hypoglycemia, tremor, headache, dizziness, constipation.
  • Anti-Diabetic agents